'Yumanity' possible: $45M series A to propel pipeline to the clinic
Yumanity Therapeutics pulled down a $45 million series A led by Fidelity Management & Research Co. "the investment group, not the venture group," Tony Coles, chairman and CEO, clarified in a vote of institutional confidence that "almost never happens" in an early round, he said.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST